Min‐Hee Ryu
Min‐Hee Ryu publishes mostly in Pulmonary and Respiratory Medicine, Oncology and Surgery, on topics such as Gastric Cancer Management and Outcomes, Gastrointestinal Tumor Research and Treatment and Colorectal Cancer Treatments and Studies.
- World rank
- #138,092 of 7,710,434 ranked researchers
- Rank in South Korea
- #720 of 162,609
- Works
- 519
- Citations
- 19k
- Citations per work
- 37.4
What does Min‐Hee Ryu research?
Min‐Hee Ryu's work is mostly in Medicine (79%), Biochemistry, Genetics and Molecular Biology (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences41279.4%
- Medicine41279.4%
- Everything else8917.1%
- Life Sciences183.5%
- 1Pulmonary and Respiratory Medicine27% of their works
- 2Oncology21% of their works
- 3Surgery17% of their works
- 4Gastroenterology11% of their works
- 5Hepatology4% of their works
- 6Molecular Biology4% of their works
Research topics
- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastrointestinal disorders and treatments
Which keywords describe Min‐Hee Ryu's research?
The keywords of their largest research topics: Chemotherapy, Endoscopic Resection, Clinical Practice Guidelines, Gastric Cancer, Molecular Characterization, Prognostic Factors, Surgical Management and Epidemiology.
- Meckel's Diverticulum
- Liver Cancer
- Cholangiocarcinoma
- Preoperative Chemoradiotherapy
- PD-1 and PD-L1
- Treatment
- KRAS Mutations
- Sunitinib
- Epidemiology
- Prognostic Factors
- Gastric Cancer
- Endoscopic Resection
- Chemotherapy
- Clinical Practice Guidelines
- Molecular Characterization
- Surgical Management
- Imatinib Mesylate
- Cetuximab
- Diagnosis
- Immune Checkpoint Blockade
- Esophageal Carcinoma
- Biliary Tract Cancer
- Hepatocellular Carcinoma
- Intussusception
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 24 words, with their numbers
- Chemotherapy3442 topics
- Endoscopic Resection3042 topics
- Clinical Practice Guidelines2982 topics
- Gastric Cancer2481 topic
- Molecular Characterization2481 topic
- Prognostic Factors1722 topics
- Surgical Management1722 topics
- Epidemiology1543 topics
- Imatinib Mesylate1191 topic
- Sunitinib1191 topic
- Cetuximab961 topic
- KRAS Mutations961 topic
- Diagnosis952 topics
- Treatment952 topics
- Immune Checkpoint Blockade581 topic
- PD-1 and PD-L1581 topic
- Esophageal Carcinoma561 topic
- Preoperative Chemoradiotherapy561 topic
- Biliary Tract Cancer531 topic
- Cholangiocarcinoma531 topic
- Hepatocellular Carcinoma501 topic
- Liver Cancer501 topic
- Intussusception451 topic
- Meckel's Diverticulum451 topic
Where does Min‐Hee Ryu work?
Min‐Hee Ryu's main affiliation in the publication record is Asan Medical Center, South Korea.
How many publications and citations does Min‐Hee Ryu have?
OpenAlex counts 519 works and 19,425 citations for Min‐Hee Ryu, an h-index of 59, ranking #138,092 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Other researchers named Min‐Hee Ryu
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Min‐Hee Ryu. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.